

# <sup>64</sup>Cu

- [<sup>64</sup>Cu](1-*N*-(4-aminobenzyl)-3,6,10,13,16,19-hexaazabicyclo[6.6.6]-eicosane-1,8-diamine)-anti-GD2 monoclonal antibody
- [<sup>64</sup>Cu]-1,4,7,10-Tetra-azacyclododecane-*N,N',N'',N'''*-tetraacetic acid conjugated knottin 2.5D
- [<sup>64</sup>Cu]-1,4,7,10-Tetra-azacyclododecane-*N,N',N'',N'''*-tetraacetic acid conjugated knottin 2.5F
- <sup>64</sup>Cu-[Ac-NIe-Asp-His-D-Phe-Arg-Trp-Gly-Lys(1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid)-NH<sub>2</sub>]
- <sup>64</sup>Cu-[cinnamoyl-Phe-D-Leu-Phe-D-Leu-Phe-Lys(PEG-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid)-NH<sub>2</sub>]
- <sup>64</sup>Cu-{*N*-[1,4,8,11-Tetraazacyclotetradecanyl-1,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine}
- <sup>64</sup>Cu-1,4,7,10-4,11-Bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-rhenium-cyclized-[Cys<sup>3,4,10</sup>,D-Phe<sup>7</sup>,Arg<sup>11</sup>]α-MSH<sub>3-13</sub>
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-vascular endothelial growth factor
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-anti-CD105 TRC105 chimeric monoclonal antibody
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-Arg-Arg-Natl-Cys-Tyr-Cit-Lys-D-Lys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub>
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-Arg-rich Cys knot scaffold grafted with integrin α<sub>v</sub>β<sub>6</sub>-binding peptide RSLARTDLDHLRGR
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-Arg-rich Cys knot scaffold grafted with integrin α<sub>v</sub>β<sub>6</sub>-binding peptide RSLARTDLDHLRGR
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-Asp-Gly-Glu-Ala
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-cyclo(CGNSNPKSC)
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-epidermal growth factor receptor-binding fibronectin domain E13.4.3'
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-Ser-rich Cys knot scaffold grafted with integrin α<sub>v</sub>β<sub>6</sub>-binding peptide RSLARTDLDHLRGR

- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid-(Gly-Ser-Gly)-Lys-Cys-Cys-Tyr-Ser-Leu
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid-human serum albumin-Ac-Cys-Z<sub>EGFR:1907</sub>
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidethylacetamide-Ac-Cys-Z<sub>EGFR:1907</sub>
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-1,4,7-Tris-acetic acid-10-maleimidoethylacetamide-ACEQNPIYWARYADWLFTTPLLDDLALLVDADEGTG
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-1,4,7-β max tris(acetic acid)-10-acetate mono(*N*-ethylmaleimide amide)-dimeric (Z<sub>HER2:477</sub>)<sub>2</sub>
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-1,4,7-β max tris(acetic acid)-10-acetate mono(*N*-ethylmaleimide amide)-monomeric Z<sub>HER2:477</sub>
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-anti-prostate-specific membrane antigen 3/A12 monoclonal antibody
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-Asp-cyclohexylalanine-Phe-<sub>D</sub>-Ser-<sub>D</sub>-Arg-Tyr-Leu-Trp-Ser
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-Asp-cyclohexylalanine-Phe-<sub>D</sub>-Ser-<sub>D</sub>-Arg-Tyr-Leu-Trp-Ser-NH<sub>2</sub> (AE105-NH<sub>2</sub>)
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-cetuximab
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-C-type atrial natriuretic factor
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid- cyclic arginine-glycine-aspartic acid peptide
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-E{E{c(RGDyK)}<sub>2</sub>}<sub>2</sub> peptide
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-E{E{c(RGDfK)}<sub>2</sub>}<sub>2</sub>
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-E{E{c(RGDyK)}<sub>2</sub>}<sub>2</sub>
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-HB22.7
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-interleukin-18-binding protein-Fc

- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-panitumumab
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-*p*-benzyl-NH-hu14.18K322A
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-PEGylated cyclic arginine-glycine-aspartic acid peptide
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-PEGylated dimeric cyclic arginine-glycine-aspartic acid peptide
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-polyethylene glycol 12 anti-tumor-associated glycoprotein 72 diabody
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-polyethylene glycol 27 anti-tumor-associated glycoprotein 72 diabody
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-polyethylene glycol-single-chain Cys-tagged vascular endothelial growth factor-121
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-polyethylene-glycol-single-walled nanotube-c(RGDyK)
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-T84.66 scFv-human serum albumin
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-vascular endothelial growth factor-121(D63AE64AE67A)
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-1,4,7,10-tetraacetic acid-rhenium-cyclized-[Cys<sup>3,4,10</sup>,D-Phe<sup>7</sup>,Arg<sup>11</sup>]α-MSH<sub>3-13</sub>
- <sup>64</sup>Cu-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid agouti-related protein-7C
- <sup>64</sup>Cu-1,4,7-Triazacyclononane,1-glutaric acid-4,7-acetic acid-cyclo(Arg-Gly-Asp-D-Phe-Lys)
- <sup>64</sup>Cu-1,4,7-Triazacyclononane,1-glutaric acid-4,7-acetic acid-cyclo(Arg-Gly-Asp-D-Tyr-Lys)
- <sup>64</sup>Cu-1,4,7-Triazacyclononane,1-glutaric acid-4,7-acetic acid-*p*-Cl-Phe-cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH<sub>2</sub>
- <sup>64</sup>Cu-1,4,7-Triazacyclononane-1,4,7-triacetic acid-Arg-Arg-Natl-Cys-Tyr-Cit-Lys-D-Lys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub>
- <sup>64</sup>Cu-1,4,7-Triazacyclononane-1,4,7-triacetic acid-*p*-isothiocyanatobenzyl-ALT-836
- <sup>64</sup>Cu-1,4,7-Triazacyclononane-1,4,7-triacetic acid-8-aminooctanoic acid-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH<sub>2</sub>

- <sup>64</sup>Cu-1,4,7-Triazacyclononane-1,4-7-triacetic acid-Glu-c(RGDyK)-bombesin[7-14]
- <sup>64</sup>Cu-1,4,7-Triazacyclononane-1,4-diacetate-8-aminooctanoic acid-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH<sub>2</sub>
- <sup>64</sup>Cu-1,4,7-Triazacyclononane-1,4-diacetic acid-(Gly-Ser-Gly)-Lys-Cys-Cys-Tyr-Ser-Leu
- <sup>64</sup>Cu-1,4,7-Triazacyclononane-1,4-diacetic acid-6-aminohexanoic acid-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH<sub>2</sub>
- <sup>64</sup>Cu-1,4,7-Triazacyclononane-1,4-diacetic acid-9-aminonanoic acid-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH<sub>2</sub>
- <sup>64</sup>Cu-1,4,7-Triazacyclononane-1,4-diacetic acid-c(RGDyK)-Glu-6-aminohexanoic acid-bombesin[7-14]NH<sub>2</sub>
- <sup>64</sup>Cu-1,4,7-Triazacyclononane-1,4-diacetic acid-para-aminobenzoic acid-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH<sub>2</sub>
- <sup>64</sup>Cu-1,4,8,11-Tetraazacyclotetradecane-*N,N',N'',N'''*-tetraacetic acid-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr(OH)
- <sup>64</sup>Cu-1,4,8,11-Tetraazacyclotetradecane-regioselectively addressable functionalized template-[cyclo-(Arg-Gly-Asp-D-Phe-Lys)]<sub>4</sub>
- <sup>64</sup>Cu-4,11-Bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-cyclic-arginine-glycine-aspartic acid peptide
- <sup>64</sup>Cu-4,11-Bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr(OH)
- <sup>64</sup>Cu-4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-LLP2A
- <sup>64</sup>Cu-4,11-Bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-p-Cl-Phe-cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH<sub>2</sub>
- <sup>64</sup>Cu-4,11-Bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-Phe(4-NO<sub>2</sub>)-cyclo(D-Cys-Tyr-D-Trp-Lys-Thr-Cys)-D-Tyr-NH<sub>2</sub>
- <sup>64</sup>Cu-Anti-human integrin  $\alpha_v\beta_3$  monoclonal antibody
- <sup>64</sup>Cu-Bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-(Gly-Ser-Gly)-Lys-Cys-Cys-Tyr-Ser-Leu
- <sup>64</sup>Cu-Bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-cyclo(Arg-Gly-Asp-D-Phe-Lys)
- <sup>64</sup>Cu-Diethylenetriamine pentaacetic acid-NH-CO-CH<sub>2</sub>-S-CH<sub>2</sub>-Phe-Pro-Arg-CH<sub>2</sub>-prothrombin
- <sup>64</sup>Cu-DOTA-[Pro<sup>1</sup>,Tyr<sup>4</sup>]-Bombesin[1-14]

- $^{64}\text{Cu}$ -DOTA hu4D5v8 (scFv- $\text{C}_6\text{H}_4$ - $\text{C}_6\text{H}_5$ )<sub>2</sub>
- $^{64}\text{Cu}$ -Labeled, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-chelated, and cysteine-modified anti-activated leukocyte cell adhesion molecule diabody
- $^{64}\text{Cu}$ -Labeled 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraazacyclotetradecane}
- $^{64}\text{Cu}$ -Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-  
VENK[homoC]NKEMRNRYWEAALDPNLNNQQKRAKIRSIYDDP[homoC]-NH<sub>2</sub>  
with a disulfide bridge between the two homoC
- $^{64}\text{Cu}$ -Labeled 1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-conjugated  
vascular endothelial growth factor A isoform 121-gelonin fusion protein
- $^{64}\text{Cu}$ -Labeled 1,4,7-tris(acetic acid)-10-vinylsulfone-1,4,7,10-tetraazacyclododecane  
conjugated to Cys<sup>40</sup>-Exendin-4
- $^{64}\text{Cu}$ -Labeled 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo [6.6.6] icosane-1-  
ylamino)methyl)benzoic acid (AmBaSar)
- $^{64}\text{Cu}$ -Labeled 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo [6.6.6] icosane-1-  
ylamino)methyl)benzoic acid (AmBaSar) conjugated to cyclic arginine-glycine-aspartic  
acid (RGD) peptide
- $^{64}\text{Cu}$ -Labeled anti-c-kit monoclonal antibody 12A8 Fab fragment
- $^{64}\text{Cu}$ -Labeled bis-1,4,7,10-tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid conjugated  
hypericin
- $^{64}\text{Cu}$ -Labeled cysteine-tagged dimeric epidermal growth factor
- $^{64}\text{Cu}$ -Labeled cysteine-tagged epidermal growth factor
- $^{64}\text{Cu}$ -Labeled DOTA conjugated anti-epithelial membrane protein 2 minibody KS83
- $^{64}\text{Cu}$ -Labeled DOTA-conjugated rituximab, a chimeric murine/human anti-CD20  
monoclonal antibody
- $^{64}\text{Cu}$ -Labeled human serum albumin-conjugated Affibody *Z<sub>HER2:342</sub>* that targets the  
human epidermal growth factor receptor 2 (HER2)
- $^{64}\text{Cu}$ -Labeled L-histidine
- $^{64}\text{Cu}$ -Labeled Lys<sup>40</sup>(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)NH<sub>2</sub>-  
conjugated exendin-4
- $^{64}\text{Cu}$ -Labeled Oxo-DO3A-conjugated trastuzumab and PCTA-conjugated trastuzumab
- $^{64}\text{Cu}$ -Labeled PEGylated nano-graphene oxide (GO) covalently linked to NOTA-  
conjugated anti-CD105 (endoglin) chimeric monoclonal antibody TRC105

$^{64}\text{Cu}$ -*N,N'*-Bis(*S*-benzoyl-thioglycoloyl)diaminopropanoate-*KRAS*-PNA-D(Cys-Ser-Lys-Cys)

$^{64}\text{Cu}$ -Polyethylenimine

$^{64}\text{Cu}$ -Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-conatumumab

$^{64}\text{Cu}$ -Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-MEDI-522

$^{64}\text{Cu}$ -Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-TNYLFSPNGPIARAW (TNYL-RAW)

$^{64}\text{Cu}$ -Z-E-(1,8-Diamino-3,6,10,13,16,19-hexaazabicyclo(6,6,6)eicosane)-aminohexanoyl-Asp-Gly-Glu-Ala

Copper 1,4,8,11-tetraazacyclotetradecane-*N,N',N'',N'''*-tetraacetic acid-octreotide

HSDAVFTDNYTKLRKQ-NIe-AVKK-(3-OCH<sub>3</sub>,4-OH)-FLNSSV-GABA-L-(Dap-(BMA)<sub>2</sub>)- $^{64}\text{Cu}$

NR-LU-10/streptavidin-copper  $^{64}$ -(1,4,7,10-tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid)-biotin